Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

被引：56
|
作者：
Alva, A. [1 ]
Csoszi, T. [2 ]
Ozguroglu, M. [3 ]
Matsubara, N. [4 ]
Geczi, L. [5 ]
Cheng, S. Y-S. [6 ]
Fradet, Y. [7 ]
Oudard, S. [8 ]
Vulsteke, C. [9 ]
Morales Barrera, R. [10 ]
Flechon, A. [11 ]
Gunduz, S. [12 ]
Loriot, Y. [13 ]
Rodriguez-Vida, A. [14 ]
Mamtani, R. [15 ]
Yu, E. Y. [16 ]
Nam, K. [17 ]
Imai, K. [18 ]
Moreno, B. H. [19 ]
Powles, T. B. [20 ]
机构：
[1] Univ Michigan, Hematol Oncol, Ann Arbor, MI 48109 USA
[2] Hetenyi G Korhaz Onkol Kozpont, Oncol, Szolnok, Hungary
[3] Istanbul Univ Cerrahpasa, Med Oncol, Cerrahpasa Sch Med, Istanbul, Turkey
[4] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[5] Natl Inst Oncol Hungary, Med Oncol, Budapest, Hungary
[6] Sunnybrook Odette Canc Ctr, Oncol, Toronto, ON, Canada
[7] Univ Laval, CHU Quebec, Surg Urol, Quebec City, PQ, Canada
[8] Hop European George Pompidou, Immunotherapie & Traitement Antiangiogen Pathol C, Paris, France
[9] Ctr Oncol Res CORE, Antwerp, Belgium
[10] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[11] Ctr Leon Berard, Dept Med Oncol, Rhones Alpes, France
[12] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkey
[13] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[14] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
[15] Univ Penn, Abramson Canc Ctr, Hematol Oncol, Philadelphia, PA 19104 USA
[16] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA
[17] Merck & Co Inc, Stat, Kenilworth, NJ USA
[18] Merck & Co Inc, Clin Res Oncol Dept, Kenilworth, NJ USA
[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[20] Queen Mary Univ London, Barts Canc Inst, Dept Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2252
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA23
引用
收藏
页码：S1155 / S1155
页数：1
相关论文
共 50 条
  • [21] Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Soulieres, D.
    Tahara, M.
    de Castro, G.
    Psyrri, A.
    Baste, N.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia, R., Sr.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Swaby, R. F.
    Gumuscu, B.
    Burtness, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S660 - S661
  • [22] Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
    Loriot, Yohann
    Powles, Thomas
    Duran, Climent Miguel Angel
    Sridhar, Srikala S.
    Bellmunt, Joaquim
    Petrylak, Daniel Peter
    Wang Jing
    Costa, Nuno Matos
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Grivas, Petros
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial
    Powles, Thomas
    Chang, Wayne Yen-Hwa
    Yamamoto, Yoshiaki
    Munoz-Langa, Jose
    Reyes, Felipe
    Peer, Avivit
    Yu, Evan Y.
    Cohen, Graham
    Lorch, Anja
    Bavle, Abhishek
    Moreno, Blanca Homet
    Markensohn, Julia
    Edmondson, Mackenzie
    Chen, Cai
    Cristescu, Razvan
    Pena, Carol Elaine
    Lunceford, Jared
    Gunduz, Seyda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance.
    Katayama, Satoshi
    Kawada, Tatsuhi
    Kobayashi, Keita
    Watanabe, Ryuta
    Tohi, Yoichiro
    Yamamoto, Shinkuro
    Takamoto, Atsushi
    Shimizu, Ryutaro
    Daizumoto, Kei
    Nagami, Taichi
    Wada, Koichiro
    Miura, Noriyoshi
    Morizane, Shuichi
    Furukawa, Junya
    Inoue, Keiji
    Sugimoto, Mikio
    Shiraishi, Koji
    Araki, Motoo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [25] Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
    Rischin, Danny
    Harrington, Kevin Joseph
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Lin, Jianxin
    Gumuscu, Burak
    Swaby, Ramona F.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
    Aragon-Ching, J. B.
    Grivas, P.
    Loriot, Y.
    Bellmunt, J.
    Wang, J.
    Michelon, E.
    di Pietro, A.
    Powles, T. B.
    Sridhar, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
  • [27] ONCOLOGISTS' PREFERENCES FOR FIRST-LINE (1L) TREATMENT OF LOCALLY ADVANCED/ UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA (AUC)
    Grivas, P.
    Phani, V
    Chiu, K.
    Pawar, V
    Chang, J.
    Bharmal, M.
    VALUE IN HEALTH, 2022, 25 (01) : S162 - S162
  • [28] Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
    Powles, T. B.
    Kopyltsov, E.
    Su, P-J.
    Parnis, F. X.
    Park, S. H.
    Yamamoto, Y.
    Fong, P. C.
    Tournigand, C.
    Duran, M. A. Climent
    Bamias, A.
    Caserta, C.
    Chang, J.
    Yan, E.
    di Pietro, A.
    Wang, J.
    Grivas, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S578 - S579
  • [29] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
    Shitara, Kohei
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles
    Wyrwicz, Lucjan
    Lee, Keun-Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Caglevic, Christian
    Villanueva, Luis
    Goekkurt, Eray
    Satake, Hironaga
    Enzinger, Peter
    Alsina, Maria
    Benson, Al
    Chao, Joseph
    Ko, Andrew H.
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, S. Peter
    Tabernero, Josep
    JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
  • [30] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Dang, T.
    Penrod, J.
    Kush, D.
    Qin, Y.
    Li, B.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
12345